A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157
Active cancer or recent cancer history : NNMT plays a complex role in cancer biology
In summary, we found several differences in lumbar disc degeneration between patients with non-specific cLBP and asymptomatic controls